key: cord-0696115-8o44eva9
authors: Klok, F. A.; MJHA, Kruip; van der Meer, N.J.M.; Arbous, M. S.; Gommers, D.; Kant, K. M.; FHJ, Kaptein; van Paassen, J.; MAM, Stals; Huisman, M. V.; Endeman, H.
title: Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis
date: 2020-04-30
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.04.041
sha: 6c12e780420c9e54bc0e1ceeef325f27014b7b01
doc_id: 696115
cord_uid: 8o44eva9

Abstract Introduction We recently reported a high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. In answering questions raised regarding our study, we updated our database and repeated all analyses. Methods We re-evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted to the ICUs of 2 Dutch university hospitals and 1 Dutch teaching hospital from ICU admission to death, ICU discharge or April 22nd 2020, whichever came first. Results We studied the same 184 ICU patients as reported on previously, of whom a total of 41 died (22%) and 78 were discharged alive (43%). The median follow-up duration increased from 7 to 14 days. All patients received pharmacological thromboprophylaxis. The cumulative incidence of the composite outcome, adjusted for competing risk of death, was 49% (95% confidence interval [CI] 41–57%). The majority of thrombotic events were PE (65/75; 87%). In the competing risk model, chronic anticoagulation therapy at admission was associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI 0.091–0.92). Patients diagnosed with thrombotic complications were at higher risk of all-cause death (HR 5.4; 95%CI 2.4–12). Use of therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35–1.8). Conclusion In this updated analysis, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia.

We recently reported a high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. In answering questions raised regarding our study, we updated our database and repeated all analyses.

We re-evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted to the ICUs of 2 Dutch university hospitals and 1 Dutch teaching hospital from ICU admission to death, ICU discharge or April 22 nd 2020, whichever came first.

We studied the same 184 ICU patients as reported on previously, of whom a total of 41 died (22%) and 78 were discharged alive (43%). The median follow-up duration increased from 7 to 14 days. All patients received pharmacological thromboprophylaxis. The cumulative incidence of the composite outcome, adjusted for competing risk of death, was 49% (95% confidence interval [CI] 41-57%). The majority of thrombotic events were PE (65/75; 87%). In the competing risk model, chronic anticoagulation therapy at admission was associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI 0.091-0.92). Patients diagnosed with thrombotic complications were at higher risk of all-cause death (HR 5.4; 95%CI 2.4-12). Use of therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35-1.8).

In this updated analysis, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia. In order to optimally respond to these questions, we decided to update our database with all thrombotic events, i.e. the composite outcome of venous thromboembolism (VTE) and arterial thrombotic complications, until April 22 nd 2020 (in the original report this was until April 5 th 2020).

We captured all confirmed diagnoses of PE, deep-vein thrombosis (DVT), ischemic stroke, myocardial infarction or systemic arterial embolism. Importantly, as in the original analysis, diagnostic tests were performed in case of clinically suspected thrombotic complications. We calculated the cumulative incidence of the composite outcome as well as the incidence adjusted for competing risk of death. The index date was the moment of ICU admission. Patients were censored upon ICU J o u r n a l P r e -p r o o f peripheral arterial embolisms. The total number of events is shown in Table 1 . The crude cumulative incidence of the composite outcome was 57% (95%CI 47-67%), and after adjustment for competing risk of death 49% (95%CI 41-57%). The incidence rate was 13/patient-year (95%CI 6.1-27). Patients diagnosed with thrombotic complications were at higher risk of all-cause death, for a HR of 5.4 (95%CI 2.4-12). A total of 17 patients (9.2%) were already on long-term therapeutic anticoagulation for various reasons, which was continued at ICU admission. In these 17 patients, 3 PEs were diagnosed. In the competing risk model, the hazard ratio (HR) for the composite outcome associated with long-term therapeutic anticoagulation was 0.29 (95%CI 0.091-0.92). Use of long-term therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35-1.8).

What are the implications of our new findings? We acknowledge the fact that cumulative incidences may overestimate the incidence of the event of interest in the setting of a high competing risk of death. We had three main reasons to report the 'crude' cumulative incidence in our first analysis. First, although the mortality rate was considerable (13%), it was only slightly higher than the threshold of 10%, after which adjustment for competing risk becomes relevant, as indicated in the letter by Lega. Second, most of the patients who died had not been referred for imaging tests to diagnose thrombotic complications. It is likely that at least some of the deceased actually had developed PE, in which case adjusting for competing risk of death could have led to an underestimation of the incidence. Lastly, many patients were still in the ICU and followed for only a few days, putting them still at continued and considerable risk of thrombotic events. We believe the validity of our initially observed 31% cumulative incidence is supported and reinforced by the observed adjusted 49% cumulative incidence of this updated analysis with a doubled observation period amounting to 14 days. Several other studies have recently presented comparable estimates, J o u r n a l P r e -p r o o f 5 "lack of clinical improvement in ventilated patients" was commonly used as a main argument to order CT pulmonary angiography after April 5 th . Interestingly, patients with thrombotic complications had a more than 5-fold higher risk of all-cause death. Although PE may contribute to respiratory failure in critically ill patients with COVID-19 pneumonia, it is possible that the most critically ill patients were more likely to be referred for imaging tests, introducing confounding by indication. In conclusion, in response to the raised questions, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia. We emphasize our advice to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and realize that our updated results will fuel the ongoing discussion on the optimal prophylactic dose of (low molecular weight) heparin in these patients. 

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Incidence of Venous Thromboembolism in Hospitalized Patients with COVID-19